Overcoming the current deadlock in antibiotic research

Till F Schäberle; Ingrid M Hack

doi:10.1016/j.tim.2013.12.007

Overcoming the current deadlock in antibiotic research

Trends Microbiol. 2014 Apr;22(4):165-7. doi: 10.1016/j.tim.2013.12.007.

Authors

Till F Schäberle¹, Ingrid M Hack²

Affiliations

¹ Institute for Pharmaceutical Biology, University of Bonn, Nussallee 6, 53115 Bonn, Germany. Electronic address: till.schaeberle@uni-bonn.de.
² Federal Ministry for Economic Cooperation and Development, Dahlmannstr. 4, 53114 Bonn, Germany.

PMID: 24698433
DOI: 10.1016/j.tim.2013.12.007

Abstract

Antibiotic-resistant bacteria are on the rise, making it harder to treat bacterial infections. The situation is aggravated by the shrinking of the antibiotic development pipeline. To finance urgently needed incentives for antibiotic research, creative financing solutions are needed. Public-private partnerships (PPPs) are a successful model for moving forward.

Keywords: antibiotic resistance; public health; public–private partnership (PPP).

MeSH terms

Anti-Bacterial Agents / economics*
Anti-Bacterial Agents / isolation & purification*
Anti-Bacterial Agents / pharmacology
Bacterial Infections / drug therapy
Capital Financing*
Drug Discovery* / economics
Drug Discovery* / methods
Drug Discovery* / trends
Drug Resistance, Bacterial
Humans
Public-Private Sector Partnerships*

Substances

Anti-Bacterial Agents